J.SamsonW
HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022SEPTEMBER 2025 TABLE 644 TERNS PHARMACEUTICALS, INC.: COMPANY OVERVIEW TABLE 645 METAVIA: COMPANY OVERVIEW TABLE 646 SCOHIA PHARMA, INC.: COMPANY OVERVIEW TABLE 647 REGOR THERAPEUTICS GROUP: COMPANY OVERVIEW TABLE 648 NEURALY INC.: COMPANY OVERVIEW TABLE 649 I2O THERAPEUTICS, INC.: COMPANY OVERVIEW TABLE 650 PFIZER INC.: COMPANY OVERVIEW TABLE 651 HANMI PHARM CO., LTD.: COMPANY OVERVIEW TABLE 652 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW TABLE 653 BIOMED INDUSTRIES, INC.: COMPANY OVERVIEW FIGURE 1 GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE FIGURE 2 GLP-1 AGONISTS MARKET: YEARS CONSIDERED FIGURE 3 GLP-1 AGONISTS MARKET: RESEARCH DESIGN FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS FIGURE 5 GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 FIGURE 6 GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024 FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS FIGURE 8 GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH FIGURE 9 CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 20252033 FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET FIGURE 11 GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY FIGURE 12 GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS
The protocol needs to be sustainable for a year or more
It is well-tolerated with essentially no side effects, making it an attractive option for patients who prefer non-pharmacological approaches
Some reviewers note the program is not well-suited to goals of 15+ lbs, and total cost for uninsured patients is the highest in our lineup
Tirzepatide (sold as Mounjaro and Zepbound) uses a similar step-up approach, starting at 2.5mg and increasing to 15mg maximum
